Arbutus Biopharma Corp (ABUS) vs MoonLake Immunotherapeutics (MLTX)

A side-by-side comparison of Arbutus Biopharma Corp and MoonLake Immunotherapeutics across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Arbutus Biopharma Corp logo
ABUS
Arbutus Biopharma Corp
$885M
$4.48HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
MoonLake Immunotherapeutics logo
MLTX
MoonLake Immunotherapeutics
$921M
$10.95HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — ABUS vs MLTX

growth of $100 · dividends reinvested · last 6y
ABUS +51.1% (+7.1%/yr)MLTX +8.5% (+1.4%/yr)ABUS compounded faster over this window
200400600Start $100202120222023202420252026$151$108
ABUS MLTX

ABUS vs MLTX: by the numbers

  • •MLTX is the larger company ($921M vs $885M market cap).
  • •ABUS is profitable (84.23% net margin) while MLTX runs a net loss (0.00%).

Metrics side by side

Valuation

MetricABUSMLTX
P/E ratio5.74N/A
Forward P/E6.05N/A
P/S ratio4.87N/A
P/B ratio3.422.15
EV / EBITDA5.90N/A

Profitability

MetricABUSMLTX
Gross margin99.98%0.00%
Operating margin-192.08%0.00%
Net margin84.23%0.00%
ROE59.16%-61.58%
ROIC54.39%-50.77%

Growth (annualized)

MetricABUSMLTX
Revenue CAGR (5Y)85.17%N/A
Total return CAGR (5Y)2.19%2.81%

Frequently asked

Is ABUS or MLTX more profitable?
ABUS runs the higher net margin — ABUS at 84.23% versus MLTX at 0.00%.
How have ABUS and MLTX total returns compared?
Over the past 5 years, ABUS delivered 2.19% and MLTX delivered 2.81% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ABUS analysisFull MLTX analysisInteractive comparison tool

Dig into the metrics

Arbutus Biopharma P/E ratioArbutus Biopharma ROEMoonLake Immunotherapeutics ROEArbutus Biopharma operating marginMoonLake Immunotherapeutics operating marginArbutus Biopharma revenue growthMoonLake Immunotherapeutics revenue growthArbutus Biopharma free cash flowMoonLake Immunotherapeutics free cash flow

Arbutus Biopharma & MoonLake Immunotherapeutics appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.